XORTX Total Other Income Expense Net from 2010 to 2024
| XRTX Stock | 1.73 0.15 7.98% |
Total Other Income Expense Net | First Reported 2010-12-31 | Previous Quarter 3.6 M | Current Value 3.8 M | Quarterly Volatility 2.8 M |
Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Net Interest Income of 266.2 K or Selling General Administrative of 1.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.89. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.
XORTX | Total Other Income Expense Net |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.